F191. THE GENETICS OF DRUG-RELATED MOVEMENT DISORDERS AN UMBRELLA REVIEW OF META-ANALYSES

摘要

BackgroundTreatment with antipsychotics can provoke drug-related movement disorders (DRMD) (also known as extrapyramidal symptoms (EPS)), i.e. tardive dyskinesia (TD), parkinsonism, akathisia and tardive dystonia. DRMD remain a cause for concern in the treatment of patients with psychotic disorders, especially because the DRMD can become irreversible (Correll and Schenk, 2008). There are lower percentages in younger patients (32%) (Mentzel 2017), but the prevalence is substantial in chronic patients (68%) (Bakker 2011), with around a quarter of chronic patients showing two different types of DRMD (Bakker 2011). DRMD can cause severe impairment in quality of life (Fujimaki 2012. In addition, a meta-analysis (Ballesteros 2000) and two recent studies showed a higher mortality in patients with tardive dyskinesia (Chong 2009, Dean and Thuras 2009). It is therefore important to find ways of preventing DRMD. Pharmacogenetic studies may identify genetic risk factors, which underlie individual vulnerability for DRMD in response to antipsychotics (Reynolds 2007; Ohmori 2003; Lerer 2002), in theory paving the way for individually tailored medication prescriptions (Lerer and Segman 2006). To date, many different papers have been written on the subject and they have presented inconsistent results.The aim of this umbrella review is to provide clinicians and patients with evidence-based information regarding the genes that are thought to be associated with DRMD and to use this umbrella review on the genetics of DRMD as a basis for recommendations for future prevention programs and research.